Literature DB >> 11502506

Diversity of SHV and TEM beta-lactamases in Klebsiella pneumoniae: gene evolution in Northern Taiwan and two novel beta-lactamases, SHV-25 and SHV-26.

F Y Chang1, L K Siu, C P Fung, M H Huang, M Ho.   

Abstract

A total of 113 blood culture isolates of Klebsiella pneumoniae from 10 hospitals in northern Taiwan were studied for SHV and TEM beta-lactamase production. bla(SHV) was amplified from all isolates by PCR. TEM-type resistance, was found in 32 of the isolates and was of the TEM-1 type in all isolates. SHV-1, -2, -5, -11, and -12 and two novel enzymes were identified. These novel enzymes were designated SHV-25 and SHV-26 and had pIs of 7.5 and 7.6, respectively. Amino acid differences in comparison to the amino acid sequence of bla(SHV-1) were found at positions T18A (ThrACC-->AlaGCC), L35Q (LeuCTA-->GluCAA), and M129V (MetATG-->ValGTG) for SHV-25 and at position A187T (AlaGCC-->ThrACC) for SHV-26. The results of substrate profiles and MIC determinations showed that the novel enzymes did not hydrolyze extended-spectrum cephalosporins, rendering the isolates susceptible to these agents. Inhibition profiles revealed that the 50% inhibitory concentration for SHV-26 was higher than those for SHV-1 and SHV-25, resulting in an intermediate resistance to amoxicillin-clavulanic acid. Forty-nine ribotypes were identified, suggesting that major clonal spread had not occurred in any of the hospitals. According to the amino acid sequence, SHV beta-lactamases in Taiwan may basically be derived through stepwise mutation from SHV-1 or SHV-11 and further subdivided by four routes. The stepwise mutations initiated from SHV-1 or SHV-11 to SHV-2, SHV-5, and SHV-12 comprise the evolutionary change responsible for extended-spectrum beta-lactamase (ESBL) production in Taiwan. The stepwise mutations that lead to a non-ESBL (SHV-25) and the beta-lactamase (SHV-26) with reduced susceptibility to clavulanic acid are possibly derived from SHV-11 and SHV-1, respectively. The results suggest a stepwise evolution of SHV beta-lactamases in Taiwan.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502506      PMCID: PMC90669          DOI: 10.1128/AAC.45.9.2407-2413.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient.

Authors:  H Marchandin; C Carriere; D Sirot; H J Pierre; H Darbas
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Extended-spectrum beta-lactamase producing strains of Enterobacter cloacae transferring resistance to cefotaxime and ceftazidime.

Authors:  J Blahová; K Králiková; V Krcméry; V Schäfer
Journal:  J Chemother       Date:  1999-04       Impact factor: 1.714

3.  Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia.

Authors:  J K Rasheed; C Jay; B Metchock; F Berkowitz; L Weigel; J Crellin; C Steward; B Hill; A A Medeiros; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

4.  Occurrence of extended-spectrum betalactamases (ESBL) in Dutch hospitals.

Authors:  E E Stobberingh; J Arends; J A Hoogkamp-Korstanje; W H Goessens; M R Visser; A G Buiting; Y J Debets-Ossenkopp; R J van Ketel; M L van Ogtrop; L J Sabbe; G P Voorn; H L Winter; J H van Zeijl
Journal:  Infection       Date:  1999 Nov-Dec       Impact factor: 3.553

5.  Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae.

Authors:  L Martínez-Martínez; A Pascual; S Hernández-Allés; D Alvarez-Díaz; A I Suárez; J Tran; V J Benedí; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 6.  Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure.

Authors:  J R Knox
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

7.  Extended-spectrum beta-lactamases in clinical isolates of enterobacteria in Mexico.

Authors:  J Silva; C Aguilar; Z Becerra; F López-Antuñano; R García
Journal:  Microb Drug Resist       Date:  1999       Impact factor: 3.431

8.  Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes.

Authors:  L K Siu; P L Lu; P R Hsueh; F M Lin; S C Chang; K T Luh; M Ho; C Y Lee
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 9.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  18 in total

1.  Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China.

Authors:  Aroonwadee Chanawong; Fatima Hannachi M'Zali; John Heritage; Jian-Hui Xiong; Peter Michael Hawkey
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in pediatric intensive care units.

Authors:  Tsu-Lan Wu; Ju-Hsin Chia; Lin-Hui Su; An-Jing Kuo; Chishih Chu; Cheng-Hsun Chiu
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

3.  Molecular analysis of the simultaneous production of two SHV-type extended-spectrum beta-lactamases in a clinical isolate of Enterobacter cloacae by using single-nucleotide polymorphism genotyping.

Authors:  Dóra Szabó; Melissa A Melan; Andrea M Hujer; Robert A Bonomo; Kristine M Hujer; Christopher R Bethel; Katalin Kristóf; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan.

Authors:  Jing-Jou Yan; Po-Ren Hsueh; Jang-Jih Lu; Feng-Yee Chang; Jainn-Ming Shyr; Jen-Hsien Wan; Yung-Ching Liu; Yin-Ching Chuang; Yi-Chueh Yang; Shih-Ming Tsao; Hsiu-Hung Wu; Li-Shin Wang; Tsuey-Pin Lin; Hsiu-Mei Wu; Hung-Mo Chen; Jiunn-Jong Wu
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain.

Authors:  Vera Manageiro; Eugénia Ferreira; Luís Albuquerque; Richard Bonnet; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

6.  Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M beta-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan.

Authors:  Ju-Hsin Chia; Chishih Chu; Lin-Hui Su; Cheng-Hsun Chiu; An-Jing Kuo; Chien-Feng Sun; Tsu-Lan Wu
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Characterization of the inhibitor-resistant SHV β-lactamase SHV-107 in a clinical Klebsiella pneumoniae strain coproducing GES-7 enzyme.

Authors:  Vera Manageiro; Eugénia Ferreira; Antony Cougnoux; Luís Albuquerque; Manuela Caniça; Richard Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

8.  Evolution of TEM-type extended-spectrum beta-lactamases in clinical Enterobacteriaceae strains in Poland.

Authors:  Anna Baraniak; Janusz Fiett; Agnieszka Mrówka; Jarosław Walory; Waleria Hryniewicz; Marek Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

9.  A novel SHV-type beta-lactamase variant (SHV-89) in clinical isolates in China.

Authors:  Jia-Bin Li; Jun Cheng; Qian Wang; Yan Chen; Ying Ye; Xue-Jun Zhang
Journal:  Mol Biol Rep       Date:  2008-06-29       Impact factor: 2.316

10.  The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.

Authors:  Nuno Mendonça; Vera Manageiro; Frédéric Robin; M José Salgado; Eugénia Ferreira; Manuela Caniça; Richard Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.